CR6086
- Generic Name
- CR6086
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27F3N2O3
- CAS Number
- 1417742-86-9
- Unique Ingredient Identifier
- SS2LQQ8094
- Background
CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).
- Associated Conditions
- -
- Associated Therapies
- -
CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Rottapharm Biotech
- Target Recruit Count
- 55
- Registration Number
- NCT05205330
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Milano, MI, Italy
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Rottapharm Biotech
- Target Recruit Count
- 248
- Registration Number
- NCT03163966
- Locations
- 🇨🇿
Institute of Rheumatology, Prague, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath